Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Kirrberger Strasse. Geb. 40, Homburg/Saar, Germany.
Curr Hypertens Rep. 2013 Aug;15(4):370-6. doi: 10.1007/s11906-013-0365-0.
Accumulating evidence has shown that the sympathetic nervous system plays an important role in the pathophysiology and progression of several chronic disorders, e.g., arterial hypertension, cardiac arrhythmias, heart failure, and in particular chronic kidney disease (CKD). Experimental and clinical studies provide evidence that sympathetic inhibition using either sympatholytic pharmacotherapy or catheter-based renal denervation has beneficial effects in patients with CKD. Randomized clinical trials are needed to characterize the underlying pathophysiological mechanisms, and systematically evaluate the therapeutic effects of sympathetic inhibition in this high-risk patient population. In this review current knowledge of the role of the sympathetic nervous system in the development and progression of CKD will be summarized, and novel treatment options targeting sympathetic nervous system activity will be discussed.
越来越多的证据表明，交感神经系统在多种慢性疾病（如动脉高血压、心律失常、心力衰竭，特别是慢性肾脏病）的病理生理学和进展中发挥重要作用。实验和临床研究表明，使用交感神经药理学或基于导管的肾去神经支配来抑制交感神经，对慢性肾脏病患者具有有益的影响。需要进行随机临床试验来描述潜在的病理生理学机制，并系统地评估在这一高危患者人群中抑制交感神经的治疗效果。在这篇综述中，将总结交感神经系统在慢性肾脏病的发生和进展中的作用的现有知识，并讨论针对交感神经系统活性的新的治疗选择。
